Magnolia Launches New Steripath® Micro Initial Specimen Diversion Device®
Magnolia develops new lightweight, low-volume, easy-to-use Initial Specimen Diversion Device® designed for the vulnerable patient population. New FDA-cleared blood culture diversion device indicated to reduce blood culture contamination (when contaminants are present, compared to standard method controls without diversion)
Mission to ZERO Aims to Reset National Benchmark
Magnolia launches nationwide initiative to raise awareness of patient safety risks caused by false-positive diagnostic results for sepsis. The goal is to drive change by reducing the national blood culture contamination benchmark, while partnering with hospitals in their mission to eliminate blood culture contamination and false positive CLABSI reporting.
Newsweek Selects Steripath as a 2020 Best Product in Infection Prevention
The Best Health Care series by Newsweek and The Leapfrog Group highlights the nation's most promising products and technologies to help patients and healthcare workers avoid infection.
Introducing Steripath Gen2 with Integrated Syringe
The trusted solution for reducing blood culture contamination is now optimized for ‘hard stick’ patients and syringe collection protocols as the only diversion device with a preassembled, integrated syringe configuration.
New Congressional Directive for Improved VA Patient Care Enabled by Magnolia Medical’s Sepsis Testing Accuracy Technology
Patented Steripath® Initial Specimen Diversion Device® supports bill passed by U.S. House of Representatives by delivering sustained zero or near-zero blood culture contamination rates for…